Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.

B Suhler, Eric; Adán, Alfredo; P Brézin, Antoine; Fortin, Eric; Goto, Hiroshi; J Jaffe, Glenn; Kaburaki, Toshikatsu; Kramer, Michal; L Lim, Lyndell; Muccioli, Cristina; Dong Nguyen, Quan; Van Calster, Joachim; Cimino, Luca; Kron, Martina; P Song, Alexandra; Liu, Jianzhong; Pathai, Sophia; Camez, Anne; Schlaen, Ariel; E J van Velthoven, Mirjam; T Vitale, Albert; Zierhut, Manfred; Tari, Samir; D Dick, Andrew

doi:10.1016/j.ophtha.2017.12.039

Public

Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.

Published in Ophthalmology • Jul 1, 2018

NobleIDark:/48914/w1/20260526/F888A12BRecord on NobleID

Authors:

Eric B Suhler

,

Alfredo Adán

,

Antoine P Brézin

Abstract

PURPOSE: To evaluate safety and efficacy of adalimumab in patients with noninfectious intermediate, posterior, or panuveitis. DESIGN: Phase 3, open-label, multicenter clinical trial extension (VISUAL III). PARTICIPANTS: Adults meeting treatment failure (TF) criteria or who completed VISUAL I or II (...

Discussions